Blend Hopes To Improve Upon Performance Of Antibody-Drug Conjugates
This article was originally published in The Pink Sheet Daily
Executive Summary
While its most advanced program is a prodrug of cisplatin designed to enter tumors as they absorb albumin, Blend is particularly excited about Pentarins, its novel class of conjugated cancer therapeutics.